Buy Vytorin through the unique service that maximize your savings

Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia)
FDA Investigates a Report from the SEAS Trial

This information reflects FDA’s current analysis of available data concerning these drugs. Posting this…

Jan. 25, 2008 — The FDA says it will explore the medical mystery of why Vytorin cuts cholesterol but doesn’t seem to reduce plaque in the arteries.
Vytorin is a combination of two different types of cholesterol-lowering drugs: Zetia, which blocks cholesterol absorption in the gut, and Zocor, one of the statin drugs that slows cholesterol production. Other statins include Crestor…

IN WASHINGTON, the saying goes, it’s not the crime but the cover-up that gets you.
Merck/Schering-Plough’s Vytorin debacle isn’t Watergate. It’s not even on par with some of the recent safety scandals still sendi…

MUNICH, Germany — Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with caution until more is known, editors of a leading medical journal urged Tuesday.
The New England Journal of Medicine published results online from one study and an analysis of partial results from two oth…

A controversial study showing that the blockbuster cholesterol-lowering drug Vytorin failed to slow the buildup of artery plaques more than a cheaper statin is certain to provoke questions among heart patients taking Vytorin or its sister drug Zetia. USA TODAY medical reporter Steve Sternberg asked Steven Nissen, the Cleveland Clinic’s chief of cardiology, and Roger Blumenthal of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and the Americ…

M2 PRESSWIRE-17 February 2006-Research and Markets: Pfizers Atorvastatin Torcetrapib Combination is Expected to Have a Major Impact on the Dyslipidemia Market and is Expected to Compete with Both Atorvastatin and Vytorin(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:17022006 Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c33178) has announced the addition of Commercial Insight: Antidyslipidemics - Statins Hit …

2 de septiembre de 2008 — Datos recientes que sugieren que el frmaco para
reducir el colesterol
Vytorin aumenta el riesgo de cncer no pueden an ser descartados, afirma
el editor de la revista The New England Journal of Medicine.
Los inquietantes datos sobre el cncer provienen de un ensayo clnico
llamado SEAS, presentados hoy en una importante con…

New research finds no definitive link between Vytorin and cancer risk, but it also suggests that the cholesterol-lowering drug cannot curb cardiovascular disease.
The results of a small study published recently suggested that Vytorin (ezetimibe) might boost the chances of developing cancer. In that study, called SEAS, researchers found that among patients taking Vytorin, 101 developed cancer, compared with 65 in the control grou…

REPS. JOHN Dingell and Bart Stupak aren’t only interested in Lipitor advertising. In the wake of the release of ENHANCE trial data, the duo sent letters to Merck and Schering-Plough vowing an investigation and making clear that DTC ads for the …

Byline: RICH THOMASELLI
The video shows the oh-so-familiar commercial for cholesterol drug Vytorin, in which benign-looking “aunts” and “uncles” are dressed up to look like platefuls of fatty foods. What’s different, however, is the voice-over: “Nobody knows if Vytorin is safe or effective, but with enough sc…